RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo

Journal of Controlled Release

Volumn 196, Issue , 2014, Pages 234-242

  Baek, Si Eun ^a   Lee, Kwang Hyun ^a   Park, Yong Serk ^b   Oh, Deok Kun ^a   Oh, Sangtaek ^c   Kim, Keun Sik ^d   Kim, Dong Eun ^a  

^a Konkuk University   (South Korea)

^b Yonsei University Wonju   (South Korea)

^c Kookmin University   (South Korea)

^d Konyang University   (South Korea)

Author keywords

Drug delivery; Liposome; RNA aptamer; Targeting

Indexed keywords

LIPOSOMES;

ANTI-CANCER DRUG DELIVERY; CANCER CELLS; CONJUGATED LIPOSOMES; IN-VIVO; RNA APTAMER; TARGETING;

DRUG DELIVERY;

APTAMER; APTAMOSOME; DOXORUBICIN; DRUG VEHICLE; LIPOSOME; NANOPARTICLE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DNA; MICELLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER SIZE; CANCER TISSUE; CELL SURFACE; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RETENTION; DRUG UPTAKE; ENCAPSULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOSOMAL DELIVERY; LNCAP CELL LINE; MALE; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM; TARGET CELL; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; NUDE MOUSE; PROCEDURES; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CELL SURVIVAL; DNA; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; PHARMACEUTICAL VEHICLES; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908319417     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.10.018     Document Type: Article

References (36)

1. D.A. Giljohann, D.S. Seferos, W.L. Daniel, M.D. Massich, P.C. Patel, and C.A. Mirkin Gold nanoparticles for biology and medicine Angew. Chem. Int. Ed. 49 2010 3280 3294
2. R.A. Petros, and J.M. DeSimone Strategies in the design of nanoparticles for therapeutic applications Nat. Rev. Drug Discov. 9 2010 615 627
3. J. Shi, A.R. Votruba, O.C. Farokhzad, and R. Langer Nanotechnology in drug delivery and tissue engineering: from discovery to applications Nano Lett. 10 2010 3223 3230
4. M. Ferrari Cancer nanotechnology: opportunities and challenges Nat. Rev. Cancer 5 2005 161 171
5. C.O. Noble, D.B. Kirpotin, M.E. Hayes, C. Mamot, K. Hong, J.W. Park, C.C. Benz, J.D. Marks, and D.C. Drummond Development of ligand-targeted liposomes for cancer therapy Expert Opin. Ther. Targets 8 2004 335 353
6. X. Yu, Y. Zhang, C. Chen, Q. Yao, and M. Li Targeted drug delivery in pancreatic cancer Biochim. Biophys. Acta 1805 2010 97 104
7. P. Sapra, and T.M. Allen Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs Cancer Res. 62 2002 7190 7194
8. P. Sapra, and T.M. Allen Ligand-targeted liposomal anticancer drugs Prog. Lipid Res. 42 2003 439 462
9. Z. Cao, R. Tong, A. Mishra, W. Xu, G.C. Wong, J. Cheng, and Y. Lu Reversible cell-specific drug delivery with aptamer-functionalized liposomes Angew. Chem. Int. Ed. 48 2009 6494 6498
10. D.B. Kirpotin, D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, U.B. Nielsen, J.D. Marks, C.C. Benz, and J.W. Park Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res. 66 2006 6732 6740
11. J.H. Lee, M.V. Yigit, D. Mazumdar, and Y. Lu Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates Adv. Drug Deliv. Rev. 62 2010 592 605
12. A.D. Ellington, and J.W. Szostak In vitro selection of RNA molecules that bind specific ligands Nature 346 1990 818 822
13. C. Tuerk, and L. Gold Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 1990 505 510
14. S.M. Nimjee, C.P. Rusconi, and B.A. Sullenger Aptamers: an emerging class of therapeutics Annu. Rev. Med. 56 2005 555 583
15. M. Blank, T. Weinschenk, M. Priemer, and H. Schluesener Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. Selective targeting of endothelial regulatory protein pigpen J. Biol. Chem. 276 2001 16464 16468
16. C. Wang, M. Zhang, G. Yang, D. Zhang, H. Ding, H. Wang, M. Fan, B. Shen, and N. Shao Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment J. Biotechnol. 102 2003 15 22
17. D.A. Daniels, H. Chen, B.J. Hicke, K.M. Swiderek, and L. Gold A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment Proc. Natl. Acad. Sci. 100 2003 15416 15421
18. F. Gu, L. Zhang, B.A. Teply, N. Mann, A. Wang, A.F. Radovic-Moreno, R. Langer, and O.C. Farokhzad Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers Proc. Natl. Acad. Sci. 105 2008 2586 2591
19. S. Dhar, F.X. Gu, R. Langer, O.C. Farokhzad, and S.J. Lippard Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles Proc. Natl. Acad. Sci. 105 2008 17356 17361
20. Y. Kaneda Virosomes: evolution of the liposome as a targeted drug delivery system Adv. Drug Deliv. Rev. 43 2000 197 205
21. A. Wagner, M. Platzgummer, G. Kreismayr, H. Quendler, G. Stiegler, B. Ferko, G. Vecera, K. Vorauer-Uhl, and H. Katinger GMP production of liposomes - a new industrial approach J. Liposome Res. 16 2006 311 319
22. H. Kang, M.B. O'Donoghue, H. Liu, and W. Tan A liposome-based nanostructure for aptamer directed delivery Chem. Commun. 46 2010 249 251
23. M.C. Willis, B.D. Collins, T. Zhang, L.S. Green, D.P. Sebesta, C. Bell, E. Kellogg, S.C. Gill, A. Magallanez, S. Knauer, R.A. Bendele, P.S. Gill, and N. Janjic Liposome-anchored vascular endothelial growth factor aptamers Bioconjug. Chem. 9 1998 573 582
24. J. Woo, G.N. Chiu, G. Karlsson, E. Wasan, L. Ickenstein, K. Edwards, and M.B. Bally Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes Int. J. Pharm. 349 2008 38 46
25. C. Mamot, D.C. Drummond, U. Greiser, K. Hong, D.B. Kirpotin, J.D. Marks, and J.W. Park Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells Cancer Res. 63 2003 3154 3161
26. S.E. Lupold, B.J. Hicke, Y. Lin, and D.S. Coffey Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen Cancer Res. 62 2002 4029 4033
27. E. Kim, Y. Jung, H. Choi, J. Yang, J.S. Suh, Y.M. Huh, K. Kim, and S. Haam Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex Biomaterials 31 2010 4592 4599
28. J.N. Moreira, T. Ishida, R. Gaspar, and T.M. Allen Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity Pharm. Res. 19 2002 265 269
29. V. Bagalkot, O.C. Farokhzad, R. Langer, and S. Jon An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform Angew. Chem. Int. Ed. 45 2006 8149 8152
30. K. Min, H. Jo, K. Song, M. Cho, Y.S. Chun, S. Jon, W.J. Kim, and C. Ban Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers Biomaterials 32 2011 2124 2132
31. N. Dos Santos, K.A. Cox, C.A. McKenzie, F. van Baarda, R.C. Gallagher, G. Karlsson, K. Edwards, L.D. Mayer, C. Allen, and M.B. Bally pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol Biochim. Biophys. Acta 1661 2004 47 60
32. L.D. Mayer, M.B. Bally, and P.R. Cullis Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient Biochim. Biophys. Acta 857 1986 123 126
33. H. Liu, A.K. Rajasekaran, P. Moy, Y. Xia, S. Kim, V. Navarro, R. Rahmati, and N.H. Bander Constitutive and antibody-induced internalization of prostate-specific membrane antigen Cancer Res. 58 1998 4055 4060
34. O.C. Farokhzad, J. Cheng, B.A. Teply, I. Sherifi, S. Jon, P.W. Kantoff, J.P. Richie, and R. Langer Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc. Natl. Acad. Sci. 103 2006 6315 6320
35. W. Xu, I.A. Siddiqui, M. Nihal, S. Pilla, K. Rosenthal, H. Mukhtar, and S. Gong Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer Biomaterials 34 2013 5244 5253
36. 225Ac for potential targeted antivascular alpha-particle therapy of cancer J. Nucl. Med. 55 2014 107 114